Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study

The aim of the study was to assess the potential role of glucocorticoids (GC) in modulating systemic and pulmonary inflammatory responses in mechanically ventilated patients with severe pneumonia. Twenty mechanically ventilated patients with pneumonia treated at a respiratory intensive care unit (RICU) of a 1,000-bed teaching hospital were prospectively studied. All patients had received prior antimicrobial treatment. Eleven patients received GC (mean+/-SD dose of i.v. methylprednisolone 677+/-508 mg for 9+/-7 days), mainly for bronchial dilatation. Serum and bronchoalveolar lavage fluid (BALF) tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6 and C-reactive protein levels were measured in all patients. The inflammatory response was attenuated in patients receiving GC, both systemically (IL-6 1,089+/-342 versus 630+/-385 pg x mL(-1), p=0.03; C-reactive protein 34+/-5 versus 19+/-5 mg x L(-1), p=0.04) and locally in BALF (TNF-alpha 118+/-50 versus 24+/-5 pg x mL(-1), p= 0.05; neutrophil count: 2.4+/-1.1 x 10(9) cells x L(-1) (93+/-3%) versus 1.9+/-1.8 x 10(9) cells x L(-1) (57+/-16%), p=0.03). Four of the 11 (36%) patients receiving GC died compared to six (67%) who were not receiving GC (p=0.37). The present pilot study suggests that glucocorticoids decrease systemic and lung inflammatory responses in mechanically ventilated patients with severe pneumonia receiving antimicrobial treatment.

This article has been cited by other articles:

				J D Chalmers, A Singanayagam, M P Murray, C Scally, A Fawzi, and A T Hill Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia Thorax, July 1, 2009; 64(7): 592 - 597. [Abstract] [Full Text] [PDF]

				Y. J. Kim, K. M. Pack, E. Jeong, J. O. Na, Y-M. Oh, S. D. Lee, W. S. Kim, D. S. Kim, W. D. Kim, and T. S. Shim Pulmonary tuberculosis with acute respiratory failure Eur. Respir. J., December 1, 2008; 32(6): 1625 - 1630. [Abstract] [Full Text] [PDF]

				I. I. Siempos, K. Z. Vardakas, P. Kopterides, and M. E. Falagas Adjunctive therapies for community-acquired pneumonia: a systematic review J. Antimicrob. Chemother., October 1, 2008; 62(4): 661 - 668. [Abstract] [Full Text] [PDF]

				O. Sibila, C. M. Luna, C. Agusti, S. Baquero, S. Gando, J. R. Patron, J. G. Morato, R. Absi, N. Bassi, and A. Torres Effects of glucocorticoids in ventilated piglets with severe pneumonia Eur. Respir. J., October 1, 2008; 32(4): 1037 - 1046. [Abstract] [Full Text] [PDF]

				O. Sibila, C. Agusti, and A. Torres Corticosteroids in severe pneumonia Eur. Respir. J., August 1, 2008; 32(2): 259 - 264. [Abstract] [Full Text] [PDF]

				R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy J. Antimicrob. Chemother., July 1, 2008; 62(1): 5 - 34. [Abstract] [Full Text] [PDF]

				S. Gotoh, N. Nishimura, O. Takahashi, H. Shiratsuka, H. Horinouchi, H. Ono, N. Uchiyama, and N. Chohnabayashi Adrenal function in patients with community-acquired pneumonia Eur. Respir. J., June 1, 2008; 31(6): 1268 - 1273. [Abstract] [Full Text] [PDF]

				R Menendez, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, and A Torres Markers of treatment failure in hospitalised community acquired pneumonia Thorax, May 1, 2008; 63(5): 447 - 452. [Abstract] [Full Text] [PDF]

				C. Garcia-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana, and J. Garau Effects of systemic steroids in patients with severe community-acquired pneumonia Eur. Respir. J., November 1, 2007; 30(5): 951 - 956. [Abstract] [Full Text] [PDF]

				R. Menendez and A. Torres Treatment Failure in Community-Acquired Pneumonia Chest, October 1, 2007; 132(4): 1348 - 1355. [Abstract] [Full Text] [PDF]

				Z. Thomas and G. L Fraser An Update on the Diagnosis of Adrenal Insufficiency and the Use of Corticotherapy in Critical Illness Ann. Pharmacother., September 1, 2007; 41(9): 1456 - 1465. [Abstract] [Full Text] [PDF]

				S. K Gorman, R. S Slavik, and J. Marin Corticosteroid Treatment of Severe Community-Acquired Pneumonia Ann. Pharmacother., July 1, 2007; 41(7): 1233 - 1237. [Abstract] [Full Text] [PDF]

				A. Torres and R. Menendez Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur. Respir. J., August 1, 2006; 28(2): 262 - 263. [Full Text] [PDF]

				M. Confalonieri, R. Urbino, A. Potena, M. Piattella, P. Parigi, G. Puccio, R. Della Porta, C. Giorgio, F. Blasi, R. Umberger, et al. Hydrocortisone Infusion for Severe Community-acquired Pneumonia: A Preliminary Randomized Study Am. J. Respir. Crit. Care Med., February 1, 2005; 171(3): 242 - 248. [Abstract] [Full Text] [PDF]

				C. Agusti, A. Rano, X. Filella, J. Gonzalez, A. Moreno, A. Xaubet, and A. Torres Pulmonary Infiltrates in Patients Receiving Long-term Glucocorticoid Treatment: Etiology, Prognostic Factors, and Associated Inflammatory Response Chest, February 1, 2003; 123(2): 488 - 498. [Abstract] [Full Text] [PDF]

				J. ANGRILL, C. AGUSTI, R. DE CELIS, X. FILELLA, A. RANO, M. ELENA, J. P. DE LA BELLACASA, A. XAUBET, and A. TORRES Bronchial Inflammation and Colonization in Patients with Clinically Stable Bronchiectasis Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1628 - 1632. [Abstract] [Full Text] [PDF]

				T.T. Bauer, C. Arosio, C. Monton, X. Filella, A. Xaubet, and A. Torres Systemic inflammatory response after bronchoalveolar lavage in critically ill patients Eur. Respir. J., February 1, 2001; 17(2): 274 - 280. [Abstract] [Full Text] [PDF]